Read about infectious diseases, pandemics, medical advances and research in Seattle and worldwide. Local institutions include the Fred Hutchinson Cancer Research Center, UW Medicine, Harborview, Virginia Mason, Group Health and Swedish.

Alzheimer’s progression slowed by drug in major trial

Lecanemab reduced the pace of cognitive decline in people with early disease by 27% over 18 months when compared with a placebo, meeting the main goal of the trial. (Dreamstime/TNS)

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease.

More Headlines